IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Core Insights - IceCure Medical's Cryoablation System combined with stereotactic body radiation therapy (SBRT) shows a 5-year overall survival (OS) rate of 74%, significantly higher than the 41% - 52% OS rates reported for SBRT alone [1][6] - The study indicates that the combination therapy yields 5-year OS outcomes comparable to surgical options, which have an OS rate of 67% - 82% [1][6] - Lung cancer remains the most diagnosed cancer globally, with an incidence of 2.5 million cases, and is the leading cause of cancer-related deaths [1][5] Study Details - The independent study evaluated the effectiveness of combining SBRT with cryoablation for stage I non-small cell lung cancer (NSCLC) tumors measuring 2 cm [2] - A total of 64 patients with a mean tumor diameter of 2.7 cm were treated, with a median follow-up duration of 74 months [2][6] - The study was led by Dr. Hiroaki Nomori and involved multiple institutions in Japan [1][2] Results Summary - The 5-year local control rate was reported at 93% [6] - The 3-year disease-specific survival rate was 96%, and the 5-year disease-specific survival rate was 92% [6] - No treatment-related mortality was observed, although the most frequent complication post-cryoablation was pneumothorax, occurring in 40% of cases [6] Market Implications - The results of this study may significantly impact major markets, including the U.S. and Europe, by providing a minimally invasive treatment option for inoperable stage I NSCLC patients [2] - IceCure Medical's ProSense® system is positioned as a safe and effective alternative to surgical tumor removal, enhancing patient recovery and reducing complications [10][9]